Using Angelica herbal supplements to prevent prostate cancer progression
Early clinial trials for Angelica herbal supplements for prostate cancer interception
This study is looking at how a herbal supplement called Angelica gigas Nakai might help slow down prostate cancer after standard treatments like surgery or radiation haven't worked, with the goal of reducing the need for hormone therapy that can have tough side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pennsylvania State Univ Hershey Med Ctr NIH-funded |
| Lab location | 1 site (Hershey, United States) |
| Project ID | NIH-10923877 on NIH RePORTER |
What this research studies
This research investigates the potential of Angelica gigas Nakai, a herbal supplement, to intercept prostate cancer progression, particularly after conventional treatments like surgery or radiation have failed. The study aims to explore how this herbal extract can be used to delay or avoid the need for androgen deprivation therapy, which often has significant side effects. By examining the effects of Angelica on cancer progression in both animal models and human patients, the research seeks to identify effective dosages and mechanisms of action that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer who have experienced biochemical recurrence after initial treatments.
Not a fit: Patients with advanced prostate cancer who are already undergoing androgen deprivation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer alternative treatment for prostate cancer that minimizes the need for more invasive therapies.
How similar studies have performed: Previous research has shown promising results with herbal supplements in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
Hershey, United States
- Pennsylvania State Univ Hershey Med Ctr — Hershey, United States (Active)
Researchers
- Principal investigator: Lu, Junxuan — Pennsylvania State Univ Hershey Med Ctr
- Study coordinator: Lu, Junxuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.